Vitamin D Newsletter

Promoting Health and Preventing Illness with Vitamin D. Also used as an adjunct to improve treatments for Cancer, Osteoporosis, Multiple Sclerosis, Diabetes, Cardiovascular Disease and more. Read the newsletter.

A Matter of Heart and Head - NYTimes

The article on aging in the New York Times on “Old but not Frail: A Matter of Heart and Head” is instructive whether you have diabetes or not.

You must recall that diabetes represents nothing more than accelerated aging and therefore you should read the whole piece.

Another publication about diabetes fitness and aging can be found at: Diabetes Health E-Newsletter (newsletter@diabeteshealth.com)

Lastly, this is all comes together with the Mayo Clinic Proceedings from September of this year, because it reviews the better way today to measure blood pressure in “central arteries” that can determine the aging of arteries and heart. This is why we have used the Cardiovascular Profiler for the past 5 years to measure what the Mayo Clinic recommends, to keep fit as the Diabetes Health E-Newsletter recommends, and to actively reverse the heart and vascular disease of aging described in the New York Times.

It’s your time…

Hypertension Entering the Second Century of Measurement

Click here to listen to Dr. Joe's E-News. (3:30 min)

Stem Cell Town Hall - October 24, 2006

Any of you who can come and all of you who are interested in the Town Hall meeting should try to get there. It will be really good. Here's the information.

It’s your time…

The Power of L-arginine

As many of you know, I have a personal story of reversal of my hardening the arteries discovered at age 37. I had never known that it was possible to reverse hardening of the arteries until I had a follow-up CT scan five years ago that indicated that all the hardening of the arteries had disappeared.

I have never had any symptoms of cardiovascular disease. I have just finished a White Paper on the significant medical studies that show the power of L-arginine to reverse this process. It is on our website.

I am a consultant for ForMor international. There has been a change in their products steadily over the past 18 months and the Cardio Cocktail is the latest generation of what I think is an extraordinary advance in health care. Use Member Number 0131662 when you order.

I am just delighted that I don't have hardening of the arteries anymore and attribute all my success to the power of L-arginine.

ForMor is a network marketing company so if you wish to purchase some of the product you can contact our business office or the Company directly. If there are additional questions on ordering, contact us at office@endocrinemetabolic.com.

Archives - Hot Research - Diabetes

The following article supports the use of stress management and biofeedback therapy as an adjunct to medical care. We send our patients to Christine Rosche, MPH, CBT for nutritional counseling and recommend you contact her for a 30 minute introduction to biofeedback therapy and stress reduction at 650-856-3151 or at www.lightlivingprogram.com.

Archives - Hot Research - Diabetes

Once again a pilot study shows that self-regulation techniques - this time biofeedback and relaxation - are effective at reducing blood glucose levels

Researchers at the Department of Psychiatry, Medical University of Ohio in Toledo conducted randomized, controlled clinical trials to determine the effects of biofeedback and relaxation on blood glucose and HbA1c (A1C) in patients with type 2 diabetes.

Patients with type 2 diabetes were randomized to either 10 sessions of biofeedback (electromyograph and thermal) and relaxation or 3 sessions of standard patient education. All the sessions were individual. Thirty-nine subjects were entered, and 30 completed the 3-month protocol.

The study assessed average blood glucose, A1C, forehead muscle tension, and peripheral skin temperature. In addition, inventories measuring depression and anxiety were administered before randomization and after completion of the treatment or the control condition.

This pilot study found that biofeedback and relaxation were associated with significant decreases in average blood glucose, A1C, and muscle tension, as compared with the control group. At the 3-month follow-up, the treatment group continued to demonstrate lower blood glucose and A1C. Both groups had decreased scores on the depression and anxiety inventories. Patients with depression had higher blood glucose levels and were more likely to drop out of the study.

The researchers concluded that their findings supported the use of biofeedback and relaxation in patients with type 2 diabetes for up to 3 months after treatment. Nonetheless, as this was just a short term pilot study with small numbers, further research is necessary to determine the long-term effects of biofeedback and the effects of mood on patients' responses to treatment.

Citation: McGinnis RA, McGrady A, Cox SA, Grower-Dowling KA. Biofeedback-assisted relaxation in type 2 diabetes. Diabetes Care. 2005 Sep; vol. 28 (9): pages 2145-9. rmcginnis@meduohio.edu.

Alert on Counterfeit One Touch trips

FDA News
FOR IMMEDIATE RELEASE
P06-167
October 13, 2006

Media Inquiries:
Heidi Valetkevitch, 301-827-6242
Consumer Inquiries:
888-INFO-FDA

FDA Issues Nationwide Alert on Counterfeit One Touch Basic/Profile and One Touch Ultra Blood Glucose Test Strips

The U.S. Food and Drug Administration (FDA) is alerting the public to counterfeit blood glucose test strips being sold in the United States for use with various models of LifeScan, Inc., One Touch Brand Blood Glucose Monitors used by people with diabetes to measure their blood glucose.

The counterfeit test strips potentially could give incorrect blood glucose values--either too high or too low--which might result in a patient taking either too much or too little insulin and lead to serious injury or death. No injuries have been reported to FDA to date.

The counterfeit test strips are:

One Touch Basic®/Profile® (lot #272894A, 2619932 or 2606340) test strips; and,
One Touch Ultra® (lot #2691191) test strips.
Consumers who have the counterfeit test strips should stop using them, replace them immediately and contact their physician. Consumers with questions may contact the company at 1-866-621-4855.

The counterfeit test strips were distributed to pharmacies and stores nationwide--but primarily in Ohio, New York, Florida, Maryland and Missouri--by Medical Plastic Devices, Inc., Quebec, Canada and Champion Sales, Inc., Brooklyn, N.Y.

The counterfeit test strips can be identified by the following characteristics:

Counterfeit One Touch Basic/Profile Test Strips

Lot Numbers 272894A, 2619932 or 2606340
Multiple Languages- English, Greek and Portuguese text on the outer carton
Limited to 50-Count One Touch (Basic/Profile) Test Strip packages
Counterfeit One Touch Ultra Test Strips

Lot Number 2691191
Multiple Languages- English and French text on the outer carton
Limited to 50-Count One Touch Ultra Test Strip packages
LifeScan alerted FDA of the counterfeit test strips. The agency is investigating the matter.

LifeScan is alerting the public via a press release and is notifying pharmacists, distributors, and wholesalers through a letter. In its letter, the company is advising customers to contact their original source of supply for restitution. For more information, visit this web site.

FDA is alerting its Counterfeit Alert Network partners, a coalition of healthcare professional, consumer and trade associations, who have agreed to further disseminate this important information in a timely and effective manner.

Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA’s MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD, 20852-9787, or through the MedWatch Web site.

Erectile Dysfunction a Marker for Diabetes

Erectile dysfunction has often been associated with diabetes mellitus. The study done in the journal of urology, 2006 September; 176(3): 1081 – 5 was to see if this dysfunction could be a marker of diabetes mellitus.

This was using a managed care claim database from 51 health plans and 28 million members in the United States. This involved more than 1.5 million patients.

The diabetes mellitus prevalence rates were 20 percent in men with erectile dysfunction and 7.5 percent in men without erectile dysfunction. With adjustments for age, region and, current diseases, the odds of having diabetes mellitus with erectile dysfunction was significantly increased.

It was more than twice as likely to have happened in those with diabetes as opposed to those without diabetes. It was strongly so men in 45 years old or younger and likely for a 46 to 65 years old. It was not a marker for men older than 66 years.